
    
      The drug being tested in this study is called relugolix (TAK-385). Relugolix is being tested
      to treat people who have uterine fibroids.

      The study enrolled 65 patients. Participants received relugolix placebo in run in period for
      3 to 6 weeks. After run-in period, participants were randomly assigned to one of the two
      treatment groups in 1:1 ratio:

        1. Relugolix 40 mg

        2. Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has
           no active ingredient

      All participants were asked to take one tablet at the same time each day throughout the
      study.

      This multi-center trial was conducted in Japan. The overall time to participate in this study
      was 20 to 28 weeks, including run-in period of 3 to 6 weeks and a treatment period of 12
      weeks. Participants made multiple visits to the clinic, and 4 weeks after last dose of study
      drug for a follow-up assessment.
    
  